Novel Alzheimer’s drug shows positive results in Phase III trial

Written by Sharon Salt, Editor

Green Valley Pharmaceutical (Shanghai, China) has announced promising findings from a Phase III clinical trial of GV-971, a multi-targeting carbohydrate-based drug for the treatment of people with mild-to-moderate Alzheimer’s disease (AD). In the double-blind, placebo-controlled, multi-center trial, 818 people with AD were randomized to receive either GV-971 450 mg twice-daily by oral administration or placebo for a period of 36 weeks. The trial participants were aged 50–85 years old and met clinical criteria for mild-to-moderate AD. They also had MMSE scores of 11–26. The primary efficacy endpoint was the change from baseline to week 36 on the AD assessment scale-cognitive...

To view the full article, please register now for access

It's completely free